

Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2024

<https://marketpublishers.com/r/G8B76A244B2EN.html>

Date: November 2018

Pages: 400

Price: US\$ 2,800.00 (Single User License)

ID: G8B76A244B2EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global CAR T Cell Therapy Market & Clinical Trials Insight 2024' Report Highlights:

CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action

Sales Analysis of CAR - T Cell Therapy

CAR - T Cell Therapy Market Opportunity: US\$ 700 Million

CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies

CAR-T Cell Therapies in Highest Phase: Preclinical

Marketed CAR-T Cell Therapies: 2 (Yescarta & Kymriah)

Global Market Scenario of CAR T Cell Therapy

Global CAR T Cell Therapy Market Future Prospects

The research in immunotherapy has unlocked the way to harness an individual's immune response to fight against the tumors and cancers. Many of the ideas have tried to make the use of natural killer cells or B cell, however, the research has not moved a past conceptual thinking. Immuno-oncology is an evolving treatment modality with the

agents which being studied for their potential to provide the long term survival across a broad range of tumor types.

It is important to determine the advancement in this field and the use of new immunotherapies to achieve the best patient outcomes. The area of investigation is broad and includes the combining or sequencing the immunotherapies which target the immune pathways and sequencing an immunotherapeutic agent. CD-19 redirected chimeric antigen receptor is one of the immunotherapeutic modality which has been recently demonstrated the efficiency in re-inducing the remission in patients with multiply relapse B-acute lymphoblastic leukemia.

The global CAR-T cell therapy market boasts of a robust clinical pipeline under development with more than 200 products under various stages of development. As of 2018, only two products - Yescarta by Gilead Science and Kymriah by Novartis have made it into the market. Both the products have been approved by the FDA for the treatment of acute lymphoblastic leukemia (ALL), a rare type of blood cancer.

The global CAR-T cell therapy market is dominated by US due to its early entry into the segment followed by the European Union. However, owing to the growing prevalence of Blood cancer in Europe, the CAR-T cell market might become a burgeoning market in the region during the forecast period. The global CAR-T cell market is bound to grow leaps and bound with a staggering CAGR of 40%, crossing the US\$ 700 Million mark by 2024 driven by better market penetration, affordability and accessibility,.

Kuick Research report on the 'global CAR-T cell Therapy market' is a result of intensive study of the novel segment and its future market potential. The report has been made with key focus on the current market trends, CAR-T cell products and their superiority to traditional cancer therapy methods. The report also provides key insights into the market performance of existing CAR-T cell products, recent developments and market dynamics that might impact its future. The report concludes with effective forecast data and future projections which clearly highlights it as one of the most promising market in the modern cancer therapy segment.

Contents

1. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY - NEXT ERA IN IMMUNO ONCOLOGY

- 1.1 Overview
- 1.2 History & Development of CAR-T Technology

2. DEVELOPMENT OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL DESIGN

- 2.1 Structure of CAR-T Cell
- 2.2 1st Generation Chimeric Antigen Receptor
- 2.3 2nd & 3rd Generation CAR-T Cell

3. CHIMERIC ANTIGEN RECEPTOR DESIGN STANDARDS

- 3.1 CAR Modified T-Cells: Targeting
- 3.2 CAR Modified T-Cell: Signaling

4. CAR T-CELL THERAPIES DELIVERY PIPELINE & MECHANISM OF ACTION

- 4.1 Process of CAR T-Cell Therapy
- 4.2 Mechanism of Action

5. APPROACHES TO IMPROVE THE EFFICACY OF CAR-T CELL THERAPY

- 5.1 Introduction
- 5.2 Targeting the Tumor Stroma with CAR-T Cells
- 5.3 Targeting the Cytokine Networks
- 5.4 Combination Strategies for CAR-T Cells
- 5.5 Targeting the Immune Checkpoints

6. GLOBAL CAR T-CELL THERAPY - CLINICAL TRIALS FOR CANCER TREATMENT

- 6.1 Acute Lymphoblastic Leukemia
- 6.2 Multiple Myeloma
- 6.3 Brain Tumors
- 6.4 Lymphoma

6.5 Solid Tumors

7. CAR-T CELL THERAPY MARKET ANALYSIS BY PRODUCT

7.1 Kymriah by Novartis

7.2 Yescarta by Gilead

8. RECENT ADVANCES IMPACTING THE CAR - T CELL MARKET

9. SALES ANALYSIS OF CAR - T CELL THERAPY

10. COST ANALYSIS & MARKET POTENTIAL OF CAR - T CELL THERAPY

10.1 Manufacturing Cost Analysis of CAR-T Cell Therapy Products

10.2 Price Analysis of CAR-T Cell Therapy

10.3 Global - Estimated Potential Customer Base & Revenue Analysis

11. GLOBAL CAR T-CELL THERAPY MARKET OVERVIEW

11.1 Market Share of Cancer Immunotherapy by Technique

11.2 CAR-T Cell Therapy Market Value

12. GLOBAL CAR-T CELL THERAPY MARKET DYNAMICS

12.1 Favorable Parameters

12.2 Challenges

13. GLOBAL CAR-T CELL THERAPY MARKET FUTURE OUTLOOK

14. GLOBAL CAR-T CELL THERAPIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

14.1 Research

14.2 Preclinical

14.3 Clinical

14.4 Phase-I

14.5 Phase-I/II

14.6 Phase-II

15. MARKETED CAR-T CELL THERAPIES CLINICAL INSIGHT

15.1 Axicabtagene CiloleuceL (Yescarta)

15.2 TisagenlecleuceL (Kymriah)

16. COMPETITIVE LANDSCAPE

16.1 Autolus

16.2 Bellicum

16.3 Bluebird

16.4 Celgene

16.5 Cellectis

16.6 Celyad

16.7 Eureka Therapeutics

16.8 Fortress Biotech

16.9 Immune Therapeutics

16.10 Juno Therapeutics

16.11 Kite Pharma

16.12 Novartis

16.13 Sorrento therapeutics

16.14 TILT Biotherapeutics

16.15 Ziopharm

List Of Figures

LIST OF FIGURES

Figure 1-1: Historical Development of CAR-T Cell Therapy

Figure 2-1: Structure of Chimeric Antigen Receptor

Figure 2-2: First Generation Chimeric Antigen Receptor

Figure 2-3: Second Generation Chimeric Antigen Receptor

Figure 2-4: Third Generation Chimeric Antigen Receptor

Figure 3-1: Targeting Mechanism of Chimeric Antigen Receptor T-Cell

Figure 3-2: Signalling Mechanism of Chimeric Antigen Receptor T-Cell

Figure 4-1: Delivery Pipeline of CAR-T Cell Therapy Process

Figure 4-2: CAR T Cell Therapy Mechanism of Action

Figure 5-1: Strategies to Improve CAR T Cell Therapy

Figure 6-1: CAR T Cell Therapy in Brain Tumors

Figure 6-2: Chimeric Antigen Receptor Therapy in Lymphoma

Figure 6-3: Target of Cancer Cell by Chimeric Antigen Receptor

Figure 7-1: Kymriah - Product Overview

Figure 7-2: Yescarta - Product Overview

Figure 9-1: US – Total Lymphoblastic Leukemia Patients & Kymriah Eligible Patients(%), 2018

Figure 9-2: Global - Kymriah Sales (US\$ Million), 2018

Figure 10-1: Adoptive T-Cell Therapy Clinical Trials to Investigate the Efficacy & Safety (%), 2018

Figure 10-2: CAR-T cell - Estimated Manufacturing Cost (US\$), 2018

Figure 10-3: Price Analysis – CAR-T Cell Therapy (US\$/Patient), 2018

Figure 10-4: US - Distribution of CMS & out of Pocket Cost in CAR T Cell (US\$/patient), 2018

Figure 10-5: Yescarta – Complete Cost Analysis for CAR T-Cell Treatment (US\$), 2018

Figure 10-6: US - Incidence of Acute Lymphocytic Leukemia ('000'), 2018

Figure 10-7: US - Estimated Patient Base for CAR T cell Therapy (Number), 2018

Figure 10-8: US – Current Market Revenue v/s Total Potential Revenue of CAR T cell Therapy (US\$), 2018

Figure 10-9: Europe - Total Eligible Patients v/s Patients Receiving CART T Cell Treatment (Number), 2018

Figure 11-1: Cancer Immunotherapy - Market Size of CAR T Cell by Technique (%), 2018

Figure 12-1: Favorable Market Parameters of CAR T Cell Therapy

Figure 12-2: Challenges to Market Growth of CAR T Cell Therapy

Figure 13-1: Global - Cancer Immunotherapeutic Market Forecast (US\$ Billion), 2018-2024

Figure 13-2: Future Potential Immuno-Oncology

Figure 13-3: Global - CAR T Cell Therapy Market Opportunity (US\$ Million), 2018 -2024

Figure 14-1: Global - CAR-T Cell Therapies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 14-2: Global - CAR-T Cell Therapies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 14-3: Global – Discontinued CAR-T Cell Therapies Clinical Pipeline by Phase (%),2018 till 2024

Figure 14-4: Global - Discontinued CAR-T Cell Therapies Clinical Pipeline by Phase (Number), 2018 till 2024

List Of Tables

LIST OF TABLES

Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor

Table 16-1: Clinical Pipelines of Products

I would like to order

Product name: Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2024

Product link: <https://marketpublishers.com/r/G8B76A244B2EN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8B76A244B2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970